Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required. * Controlled primary tumour, defined as: * at least 3 months since original tumour treated definitively, with no progression at primary site * Total number of oligometastases of 1-5 including: * Brain metastases amenable to radiosurgery or fractionated stereotactic radiotherapy patient who had neurosurgical resection before trial inclusion are allowed and resected brain metastases count to the total number of oligometastases * All sites of disease can be safely treated based on the judgement of an experienced radiation oncologist * ECOG score 0-2 * Life expectancy \> 6 months * Age 18 or older * Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria: * Primary cancer of prostate, breast, lung or colorectal * Serious medical comorbidities precludin